AOD-9604: HGH Fragment for Fat Loss

AOD-9604 (Advanced Obesity Drug 9604) is a modified peptide fragment of human growth hormone — specifically the C-terminal segment spanning amino acids 177–191 of the 191-amino-acid GH molecule. This region contains the portion of GH responsible for its fat-burning (lipolytic) effects, but it lacks the amino acid sequences that drive growth promotion, IGF-1 elevation, and insulin resistance. The result is a targeted lipolytic compound that burns fat through mechanisms distinct from full GH, without the metabolic complications associated with GH or IGF-1 elevation.

Discovery and Development

AOD-9604 was developed by researchers at Monash University in Melbourne, Australia, and subsequently licensed to Metabolic Pharmaceuticals for clinical development. The development team led by Professor Frank Ng identified that the GH molecule's fat-mobilizing activity was concentrated in a specific C-terminal fragment, and that modifying this fragment (by adding a tyrosine residue at the N-terminus) improved its stability and potency.

After a series of Phase I, II, and IIa/IIb clinical trials, AOD-9604 received GRAS (Generally Recognized as Safe) certification from the FDA — a designation that acknowledges a compound's safety record and permits its use in food and dietary supplement formulations, though not as a therapeutic drug.

Mechanism of Action

AOD-9604 does not bind the GH receptor (GHR) that mediates GH's growth-promoting and IGF-1-stimulating effects. Instead, it appears to activate beta-3 adrenergic receptors on adipocytes — the same receptors that respond to catecholamines (adrenaline, noradrenaline) during exercise or fasting to stimulate lipolysis.

Beta-3 receptor activation triggers a cAMP cascade in fat cells that:

1. Activates hormone-sensitive lipase (HSL) and adipose triglyceride lipase (ATGL)
2. Cleaves stored triglycerides into glycerol and free fatty acids
3. Releases free fatty acids into the bloodstream for oxidation by muscle and other tissues

Because this mechanism bypasses the GH receptor, AOD-9604 does not raise IGF-1 levels, does not stimulate tissue growth or proliferation, and does not impair insulin sensitivity. It is therefore theoretically safer for long-term use in individuals with concerns about GH-axis manipulation.

In animal models, AOD-9604 also showed:

• Stimulation of fat metabolism in obese mice comparable to full GH
• No effect on cartilage or bone growth (confirming absence of GH receptor activity)
• Regulation of adipogenesis — reducing new fat cell formation

Clinical Trial Results

Phase 1: Established safety and confirmed fat-stimulating effects in healthy volunteers.

Phase 2a: 300 obese adults received various doses of oral AOD-9604. The 1 mg/day oral dose showed significant weight loss versus placebo over 12 weeks. Subcutaneous injection was also studied.

Phase 2b (SYDNEY Trial): A larger, multicenter randomized controlled trial. The results showed statistically significant fat loss at 1 mg/day versus placebo, but the effect size (approximately 1.4–1.8 kg more fat loss than placebo over 24 weeks) was considered insufficient for a pharmaceutical drug approval. Development for an obesity drug indication was discontinued.

Despite not achieving drug approval, the clinical data established AOD-9604 as safe and demonstrably lipolytic — leading to its use as a research compound and later as a GRAS-designated ingredient.

Dosage Protocol

Subcutaneous injection (most studied and effective route):

• 300 mcg per day, typically administered in the morning in a fasted state
• Some protocols use 300 mcg twice daily (morning and pre-sleep)
• Inject subcutaneously in the abdomen

Oral administration:

• 1 mg/day was the effective oral dose in clinical trials
• Bioavailability is lower oral vs. subcutaneous, necessitating the higher oral dose
• Oral AOD-9604 capsules are available from research compound suppliers

Timing: Take on an empty stomach (minimum 2 hours post-meal). Insulin significantly blunts lipolysis; fasted administration maximizes fat mobilization.

Cycle length: 12–16 weeks is the typical research protocol. Given the GRAS status and absence of hormonal disruption, some practitioners use AOD-9604 continuously during extended fat loss phases.

Advantages Over Full GH Protocols

No insulin resistance: Full GH and GH secretagogues (MK-677, CJC-1295) can impair insulin sensitivity with chronic use — a significant concern for metabolic health. AOD-9604 does not share this liability.

No IGF-1 elevation: Elevated IGF-1 from GH protocols carries theoretical long-term cancer risk considerations. AOD-9604 does not raise IGF-1, making it more appropriate for individuals with cancer risk factors.

No need for IGF-1 monitoring: Users of GH secretagogues should periodically check IGF-1 levels. AOD-9604 users require no such monitoring.

Cost: AOD-9604 is typically less expensive than tesamorelin and comparable to standard GH secretagogue protocols.

Combining AOD-9604

With intermittent fasting: AOD-9604 injected during the fasting window maximizes lipolytic effects as insulin is at its lowest and catecholamines are elevated.

With CJC-1295/ipamorelin: Some protocols combine AOD-9604 (for direct lipolysis) with GH secretagogues (for anabolic and recomposition benefits). The complementary mechanisms make this a logical combination for body recomposition.

With thyroid optimization: Thyroid hormone (T3) is the primary regulator of metabolic rate; optimizing thyroid function alongside AOD-9604 addresses both fat mobilization and fat oxidation.

FAQ

Is AOD-9604 stronger than CJC-1295 for fat loss? This depends on the context. AOD-9604 directly stimulates lipolysis without GH's side effects; CJC-1295 elevates GH, which then drives lipolysis alongside anabolic effects. For pure fat loss without anabolic goals, AOD-9604 is arguably more targeted. For body recomposition, CJC-1295 is more comprehensive.

Can AOD-9604 be used by diabetics? AOD-9604's lack of insulin resistance induction makes it theoretically more appropriate than full GH protocols for individuals with insulin resistance or type 2 diabetes. However, any peptide use in diabetics should be medically supervised.

Does AOD-9604 affect muscle mass? Unlike GH and IGF-1-elevating peptides, AOD-9604 does not have documented anabolic (muscle-building) effects. It is purely lipolytic. This makes it a fat-loss tool rather than a recomposition tool.

Related Articles

• HGH Fragment 176-191: Fat-Loss Peptide Without GH Side Effects
• Peptide Stack for Fat Loss: CJC-1295, AOD-9604, and Tesamorelin
• Afamelanotide: FDA-Approved Melanocyte Peptide
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It

Track your supplements in Optimize.